A new thiazolidinedione (TZD) based peroxisome proliferator-activated receptor (PPAR) agonist, lobeglitazone sulphate has the potential to be used therapeutically to treat type 2 diabetes mellitus. Linearity, accuracy, and precision criteria were employed to design and verify the RP-HPLC technique. to create an RP-HPLC technique that is straightforward, precise, accurate, and specific for estimating lobeglitazone sulphate. Linearity, accuracy, and precision factors were employed in the development and validation of HPLC chromatographic techniques. The acetonitrile-methanol (75:25, v/v) mobile phase was used to create the HPLC technique at a wavelength of 248 nm. 5 to 25 ug/ml was the linearity range that was observed, and the correlation value was 0.9997. The findings were statistically analysed under the ICH Q2 (R1) requirements, and the created approach was precise with a %RSD value not higher than 2 for both intra-day (1.54%) and inter-day (1.07%) precision. The findings in this paper demonstrated the invention and validation of a straightforward, quick, and economical RP-HPLC technique for lobeglitazone sulphate quantification. The developed method can be applied alone or in conjunction with the specified drugs for routine analysis and quality control.